This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simon, R. Articles by Sauter, G. Search for Related Content PubMed PubMed Citation Articles by Simon, R. Articles by Sauter, G.

KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations

¹Institute of Pathology, University of Basel, Basel, Switzerland;² Institute of Pathology, City Spital Triemli, Zürich, Switzerland; and³ Institute of Clinical Pathology, Basel, Switzerland

Purpose: KIT (CD117) is a transmembrane tyrosine kinase representing a target for STI571 (Glivec) therapy. Some KIT-overexpressing solid tumors have responded favorably to STI571, potentially because of the presence of KIT-activating mutations.

Experimental Design: To investigate the epidemiology of KIT overexpression and mutations, we investigated a series of 1654 breast cancers. All tumors were analyzed by immunohistochemistry in a tissue microarray format.

Results: KIT expression was always present in normal breast epithelium. However, cancer analysis revealed the only 43 of 1654 (2.6%) tumors were KIT-positive. KIT expression was more frequent in medullary cancer (9 of 47 positive; 19.1%) than in any other histological tumor subtype (P < 0.001). KIT expression was significantly associated with high tumor grade (P < 0.0001) but unrelated to pT and pN categories or patient survival. Mutation analysis of exons 2, 8, 9, 11, 13, and 17 was negative in 10 KIT-positive tumors.

Conclusions: Overall, our data show that a high level of KIT expression occurs infrequently in breast cancer. KIT-positive breast cancers may not reflect "KIT up-regulation" because KIT is also expressed in normal breast epithelium. The lack of KIT mutations also argues against the therapeutic efficacy of STI571 in breast cancer.

This article has been cited by other articles:

				M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., May 29, 2008; (2008) mdn352v1. [Abstract] [Full Text] [PDF]

				E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis Basal-Like Breast Cancer: A Critical Review J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581. [Abstract] [Full Text] [PDF]

				J. A. Gilbert, M. P. Goetz, C. A. Reynolds, J. N. Ingle, K. F. Giordano, V. J. Suman, H. E. Blair, R. B. Jenkins, W. L. Lingle, M. M. Reinholz, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy Mol. Cancer Ther., April 1, 2008; 7(4): 944 - 951. [Abstract] [Full Text] [PDF]

				E. J. Wasserman and A. R. Tan Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126. [Abstract] [Full Text] [PDF]

				F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]

				M. Laakso, M. Tanner, J. Nilsson, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Bergh, and J. Isola Basoluminal carcinoma: a new biologically and prognostically distinct entity between Basal and luminal breast cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4185 - 4191. [Abstract] [Full Text] [PDF]

				M. Zollo, A. Andre, A. Cossu, M. C. Sini, A. D'Angelo, N. Marino, M. Budroni, F. Tanda, G. Arrigoni, and G. Palmieri Overexpression of h-prune in Breast Cancer is Correlated with Advanced Disease Status Clin. Cancer Res., January 1, 2005; 11(1): 199 - 205. [Abstract] [Full Text] [PDF]

				K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, O. Kochli, et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer Cancer Res., December 1, 2004; 64(23): 8534 - 8540. [Abstract] [Full Text] [PDF]

				P. Th. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic, J. Kononen, A. Lugli, R. Simon, et al. Prevalence of KIT Expression in Human Tumors J. Clin. Oncol., November 15, 2004; 22(22): 4514 - 4522. [Abstract] [Full Text] [PDF]

				T. O. Nielsen, F. D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma Clin. Cancer Res., August 15, 2004; 10(16): 5367 - 5374. [Abstract] [Full Text] [PDF]

				M. T. Nevalainen, J. Xie, J. Torhorst, L. Bubendorf, P. Haas, J. Kononen, G. Sauter, and H. Rui Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis J. Clin. Oncol., June 1, 2004; 22(11): 2053 - 2060. [Abstract] [Full Text] [PDF]